Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from SinoMab Bioscience Ltd. ( (HK:3681) ).
SinoMab BioScience Limited has voluntarily withdrawn its biologics license application for SM03 (Suciraslimab) in the treatment of rheumatoid arthritis in China. This decision follows an internal assessment and recent communications with the Center for Drug Evaluation of the NMPA, highlighting the need for additional evidence of early therapeutic benefits. Despite this setback, the company remains confident in Suciraslimab’s potential and is planning new clinical development for its use in treating systemic lupus erythematosus. SinoMab continues to advance its broader pipeline, which includes multiple innovative drug candidates in various stages of development.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company focused on the development of therapeutic antibodies for the treatment of autoimmune diseases. The company’s primary products include SM03 (Suciraslimab), which is aimed at treating rheumatoid arthritis and systemic lupus erythematosus. SinoMab is committed to advancing its pipeline of clinical-stage and preclinical novel drug candidates.
Average Trading Volume: 10,378,987
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.4B
Learn more about 3681 stock on TipRanks’ Stock Analysis page.